Efavirenz-induced leukocytoclastic vasculitis.
Domingo
Pere
P
Barceló
Montserrat
M
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D048588:Benzoxazines; D001707:Biopsy, Needle; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage; D018570:Risk Assessment; D012720:Severity of Illness Index; D012867:Skin / Q000473:pathology; D018119:Stavudine / Q000008:administration & dosage; D016896:Treatment Outcome; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D019259:Lamivudine; D018119:Stavudine; C098320:efavirenz; D011241:Prednisone